HRTX Heron Therapeutics

Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.
Company profile
Ticker
HRTX
Exchange
Website
CEO
Barry Quart
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ADVANCED POLYMER SYSTEMS INC /DE/, AP PHARMA INC /DE/
SEC CIK
Corporate docs
IRS number
942875566
HRTX stock data
()
News
Heron Therapeutics Awarded U.S. Patent #10,953,018 'Formed hexagonal boron nitride body, heat-treated hexagonal boron nitride body and processes for producing the same'
23 Mar 21
12 Health Care Stocks Moving In Friday's Pre-Market Session
26 Feb 21
Heron Therapeutics Q4 EPS $(0.68) Down From $(0.65) YoY, Net Product Sales $20.60M Down From $35.08M YoY
24 Feb 21
Heron Therapeutics Highlights Publication Of Results From EPOCH 1 Follow-On Study Of HTX-001 In Patients With Undergoing Bunionectomy Surgery: '77% of Bunionectomy Patients Receiving HTX-011 Required No Opioids...'
21 Jan 21
Press releases
Thinking about buying stock in Phunware, Broadwind, Seelos Therapeutics, Golden Nugget Online Gaming, or Heron Therapeutics?
6 Apr 21
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
24 Feb 21
Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences
17 Feb 21
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
21 Jan 21
Investment data
Securities sold
Number of investors
Calendar
24 Feb 21
17 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from company earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 105.14M | 105.14M | 105.14M | 105.14M | 105.14M | 105.14M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | 20.43M | 19.01M | 17.52M | 15.4M |
Cash used (since last report) | n/a | n/a | 72.87M | 67.81M | 62.48M | 54.93M |
Cash remaining | n/a | n/a | 32.27M | 37.32M | 42.66M | 50.21M |
Runway (months of cash) | n/a | n/a | 1.6 | 2.0 | 2.4 | 3.3 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 21 | Christian Waage | Common Stock | Sell | Dispose S | No | Yes | 17.5126 | 300 | 5.25K | 4,100 |
13 Apr 21 | Lisa Peraza | Common Stock | Payment of exercise | Dispose F | No | No | 16.66 | 191 | 3.18K | 11,945 |
13 Apr 21 | Lisa Peraza | Common Stock | Option exercise | Aquire M | No | No | 0 | 552 | 0 | 12,136 |
13 Apr 21 | Lisa Peraza | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 552 | 0 | 7,729 |
13 Apr 21 | Manhard Kimberly | Common Stock | Payment of exercise | Dispose F | No | No | 16.66 | 433 | 7.21K | 1,634 |
13 Apr 21 | Manhard Kimberly | Common Stock | Option exercise | Aquire M | No | No | 0 | 1,250 | 0 | 2,067 |
13 Apr 21 | Manhard Kimberly | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,250 | 0 | 17,500 |
13 Apr 21 | John Poyhonen | Common Stock | Payment of exercise | Dispose F | No | No | 16.66 | 433 | 7.21K | 20,414 |
13 Apr 21 | John Poyhonen | Common Stock | Option exercise | Aquire M | No | No | 0 | 1,250 | 0 | 20,847 |
13 Apr 21 | John Poyhonen | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,250 | 0 | 17,500 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
13F holders |
Current |
---|---|
Total holders | 183 |
Opened positions | 25 |
Closed positions | 19 |
Increased positions | 52 |
Reduced positions | 63 |
13F shares |
Current |
---|---|
Total value | 2.07B |
Total shares | 97.87M |
Total puts | 46.8K |
Total calls | 112.8K |
Total put/call ratio | 0.4 |
Largest owners |
Shares | Value |
---|---|---|
BEN Franklin Resources | 12.69M | $268.56M |
Vanguard | 8.31M | $175.92M |
Tang Capital Partners | 7.64M | $161.61M |
Wellington Management | 6.94M | $146.8M |
BLK Blackrock | 6.89M | $145.76M |
Baker Bros. Advisors | 5.99M | $126.88M |
ArrowMark Colorado | 5.36M | $113.48M |
STT State Street | 3.98M | $84.28M |
Clearbridge Advisors | 3.45M | $73.11M |
JPM JPMorgan Chase & Co. | 3.1M | $65.63M |
Financial report summary
?Competition
Pfizer • Factset Research Systems • Durect • Glaxosmithkline • Liquidia • Vanda Pharmaceuticals • Pacira BioSciences • Acelrx Pharmaceuticals • Trevena • TesaroContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
AbCellera, Acacia, add, adult, advocacy, agonist, Albania, amidst, amisulpride, amplify, analgesia, ANJESO, antibody, arbitrage, array, Aspen, attendance, Bamlanivimab, Baudax, Biden, Bio, bridge, Bulgaria, Canadian, carryback, Casirivimab, cell, centralized, charitable, child, CHMP, Cmax, coaching, cocktail, combating, conference, conflict, coordinated, Croatia, Czech, daily, deep, demographic, developmental, disallowed, dissipate, DOJ, Durect, EC, EEA, Eli, Emergency, employed, endeavor, epidemic, epinephrine, Estesevimab, Estonia, Etesevimab, ethnicity, Europe, evidenced, excipient, expeditiously, expertise, female, field, forgiven, gender, Gilead, GLP, heading, higher, home, hotline, Hungary, hybrid, hydrochloride, Iceland, imdevimab, implant, impurity, indentured, induction, infection, Innocoll, internet, job, Junshi, justify, Latvia, leadership, Lilly, Lithuania, longevity, lowest, mAb, Macedonia, male, Mallinckrodt, Malta, Math, mentoring, Monaco, monoclonal, mortality, neutralizing, Norway, occupational, OFIRMEV, organizational, payout, peak, penetration, peptide, Pfizer, Pharmacare, phone, pill, plasma, Poland, PONV, POSIMIR, posing, postsurgical, PPP, protein, purpose, quarantining, race, recombinant, Regeneron, remdesivir, remote, reorganization, reproductive, Republic, respiratory, restaurant, risky, Romania, rulemaking, salary, Secretary, SENSORCAINE, Serbia, Shanghai, simply, slated, Slovakia, Slovenia, somatic, spike, staffed, staffing, survey, syndrome, Takeda, task, taxpayer, tie, tradipitant, trafficking, travel, tuition, Turkey, turnover, underrepresented, unfair, unpredictable, upholding, Vanda, VEKLURY, ventilation, weighting, women, worksite, worldwide, Xaracoll, ZYNRELEF
Removed:
Advanced, affiliated, AMCO, APP, APS, Bulletin, concentration, founded, Hospira, OTC, realigned, realignment, receptivity, refocused, refocusing, reincorporated, resold, revalued, scheduled
Financial reports
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
2 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
5 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
22 Feb 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
Current reports
8-K
Results of Operations and Financial Condition
24 Feb 21
8-K
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
21 Jan 21
8-K
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
11 Jan 21
8-K
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
13 Nov 20
8-K
Results of Operations and Financial Condition
5 Nov 20
8-K
Departure of Directors or Certain Officers
13 Oct 20
8-K
Heron Therapeutics Receives European Commission Authorization for ZYNRELEFTM (HTX-011) for the Treatment of Postoperative Pain
28 Sep 20
8-K
Regulation FD Disclosure
16 Sep 20
8-K
Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain
8 Sep 20
8-K
Departure of Directors or Certain Officers
5 Aug 20
Registration and prospectus
424B2
Prospectus for primary offering
7 Oct 19
424B5
Prospectus supplement for primary offering
3 Oct 19
S-8
Registration of securities for employees
5 Aug 19
424B5
Prospectus supplement for primary offering
27 Jun 18
424B5
Prospectus supplement for primary offering
25 Jun 18
424B5
Prospectus supplement for primary offering
29 Mar 18
424B5
Prospectus supplement for primary offering
27 Mar 18
424B2
Prospectus for primary offering
5 Dec 17
424B5
Prospectus supplement for primary offering
3 Dec 17
S-8
Registration of securities for employees
8 Aug 17
Proxies
DEFA14A
Additional proxy soliciting materials
23 Apr 20
DEF 14A
Definitive proxy
23 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
18 Apr 18
DEF 14A
Definitive proxy
25 Apr 17
DEFA14A
Additional proxy soliciting materials
25 Apr 17
PRE 14A
Preliminary proxy
11 Apr 17
Other
UPLOAD
Letter from SEC
21 Aug 18
CORRESP
Correspondence with SEC
29 Jul 18
UPLOAD
Letter from SEC
15 Jul 18
CT ORDER
Confidential treatment order
29 Jan 17
CT ORDER
Confidential treatment order
27 Dec 16
CT ORDER
Confidential treatment order
6 Jul 15
EFFECT
Notice of effectiveness
5 Oct 14
EFFECT
Notice of effectiveness
22 May 14
EFFECT
Notice of effectiveness
25 Aug 13
EFFECT
Notice of effectiveness
5 Sep 12
Ownership
4
HERON THERAPEUTICS / Waage Christian ownership change
16 Apr 21
4
HERON THERAPEUTICS / David Leslie Szekeres ownership change
15 Apr 21
4
HERON THERAPEUTICS / Barry D Quart ownership change
15 Apr 21
4
HERON THERAPEUTICS / JOHN POYHONEN ownership change
15 Apr 21
4
HERON THERAPEUTICS / Lisa Peraza ownership change
15 Apr 21
4
HERON THERAPEUTICS / KIMBERLY MANHARD ownership change
15 Apr 21
4
HERON THERAPEUTICS / Craig A Johnson ownership change
7 Apr 21
SC 13G/A
HERON THERAPEUTICS / BAKER BROS. ADVISORS ownership change
16 Feb 21
SC 13G/A
HERON THERAPEUTICS / TANG CAPITAL PARTNERS ownership change
16 Feb 21
SC 13G
HERON THERAPEUTICS / ArrowMark Colorado ownership change
16 Feb 21
Patents
GRANT
Utility
Emulsion formulations of aprepitant
23 Mar 21
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration.
GRANT
Utility
Long-acting polymeric delivery systems
26 Jan 21
Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent.
APP
Utility
Methods of Treating Nausea Utilizing Semi-solid Delivery Vehicle Compositions Comprising Granisetron
30 Dec 20
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle.
APP
Utility
Emulsion Formulations of an NK-1 Receptor Antagonist and Uses Thereof
9 Dec 20
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration.
APP
Utility
Emulsion Formulations of Aprepitant
24 Jun 20
Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration.
Reddit threads
Expected Biotech News 13 April 2021 to 17 June 2021 and PDUFA List for 26 April 2021 to 15 June 2021
10 Apr 21
CRSP Crispr DNA editor
7 Apr 21
Heron Therapeutics [HRTX] biotech //
5 Apr 21
Expected Biotech News 10 to 28 April 2021 and PDUFA List for 12 April 2021 to 1 June 2021
4 Apr 21
Expected Biotech News 10 to 28 April 2021 and PDUFA List for 12 April 2021 to 1 June 2021
4 Apr 21
Expected Biotech News 10 to 28 April 2021 and PDUFA List for 12 April 2021 to 1 June 2021
4 Apr 21
My Watchlist For 3/3/2021
2 Mar 21
My Watchlist For 3/3/2021
2 Mar 21